Treatment and detection of ALK-rearranged NSCLC

Solange Peters, Miquel Taron, Lukas Bubendorf, Fiona Blackhall, Rolf Stahel

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The recent approval of crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC) in the US and other countries has provoked intense interest in ALK rearrangements as oncogenic drivers, and promises to revolutionise the way in which NSCLC is diagnosed and treated. Here, we review clinical data to date for the use of crizotinib to treat patients with advanced, ALK-positive NSCLC and consider issues surrounding the detection of ALK-positivity including the use of fluorescence in situ hybridisation and the other potential techniques available, and their suitability for ALK screening. We also discuss the emergence of resistance to crizotinib therapy and the range of other ALK inhibitors currently in development. © 2013 Elsevier Ireland Ltd.
    Original languageEnglish
    Pages (from-to)145-154
    Number of pages9
    JournalLung Cancer
    Volume81
    Issue number2
    DOIs
    Publication statusPublished - Aug 2013

    Keywords

    • ALK inhibitor
    • ALK rearrangement
    • Crizotinib
    • Diagnosis
    • NSCLC
    • Resistance

    Fingerprint

    Dive into the research topics of 'Treatment and detection of ALK-rearranged NSCLC'. Together they form a unique fingerprint.

    Cite this